ライフサイエンスコーパス: drug screening

1 ant clones were detected with clone-specific drug screening.

2 igation of the biology of CRC metastasis and drug screening.

3 mechanistic studies of tumor biology and for drug screening.

4 platform for vascular disease modelling and drug screening.

5 development, as well as disease modeling and drug screening.

6 ogical application, disease diagnostics, and drug screening.

7 to have application in cellular imaging and drug screening.

8 period of abstinence and 64% requiring urine drug screening.

9 for studying specific CPVT mutations and for drug screening.

10 f a hEPC endothelialized hMSC-based TEBV for drug screening.

11 polarization form a powerful combination for drug screening.

12 uloskeletal diseases in a dish and for rapid drug screening.

13 ove the disease relevance of assays used for drug screening.

14 thereby providing an excellent platform for drug screening.

15 le for fast high throughput anti-aggregation drug screening.

16 plications such as regenerative medicine and drug screening.

17 s, can be interrogated structurally to allow drug screening.

18 a, and in cell lines through high-throughput drug screening.

19 es, examination of human-specific genes, and drug screening.

20 w beta-cells for transplantation therapy and drug screening.

21 diagnosis, protein biomarkers screening and drug screening.

22 senting a bottleneck problem for large-scale drug screening.

23 s disciplines such as patient diagnostics or drug screening.

24 in-vivo phenotypes, providing platforms for drug screening.

25 ET in preclinical therapeutic monitoring and drug screening.

26 eats of this technique and its potential for drug screening.

27 ritical when analyzing PTPs, for example, in drug screening.

28 nomics, diagnostics, directed evolution, and drug screening.

29 the in vivo toxicity of nanoparticles or for drug screening.

30 for the study of disease mechanisms and for drug screening.

31 ools in regenerative medicine, bioassay, and drug screening.

32 may be used for testing carcinogenicity and drug screening.

33 egulation of oligodendrocyte development and drug screening.

34 al PCR, single-cell analysis, and cell-based drug screening.

35 produce them in a high-throughput format for drug screening.

36 mutant, smn-1(ok355), is not well suited to drug screening.

37 sed to show the capability of the device for drug screening.

38 s of human disease mechanisms as well as for drug screening.

39 robe could be potentially used as a tool for drug screening.

40 regenerative medicine, disease modeling, and drug screening.

41 of interest in a format that is suitable for drug screening.

42 rovide a potential resource for research and drug screening.

43 in-related pathologies and allow therapeutic drug screening.

44 y cell-based system for target discovery and drug screening.

45 in microarray technology and high-throughput drug screening.

46 es used by the National Cancer Institute for drug screening.

47 sis and can serve for rapid antiangiogenesis drug screening.

48 d the lack of biological assays suitable for drug screening.

49 ary development and for disease modeling and drug screening.

50 showing great potential for high-throughput drug screening.

51 s, disease diagnostics, and chemotherapeutic drug screening.

52 nmental samples, and can also be applied for drug screening.

53 the migratory capability and anti-metastatic drug screening.

54 ential to enable more physiological in vitro drug screening.

55 n native HD tissue samples and for potential drug screening.

56 has been developed towards a high throughput drug screening.

57 the CNS to allow pharmacological testing and drug screening.

58 stem cell research, tissue engineering, and drug screening.

59 study cancer cell migration and anti-cancer drug screening.

60 lene) glycol diacrylate (PEGDA) hydrogel for drug screening.

61 e a good model for further investigation and drug screening.

62 es to perform rapid, large-scale genomic, or drug screening.

63 o use EHM for iPS-based disease modeling and drug screening.

64 ing of anti-cancer mechanism and anti-cancer drug screening.

65 iothreat detection, clinical diagnostics and drug screening.

66 ned cell types for restorative therapies and drug screenings.

67 udies of neurotransmitter-enzyme binding and drugs screening.

68 evelop automated, quantitative approaches to drug screening against helminth diseases.

69 Drug screening against helminths has often been phenotyp

70 triatal pathologies, paving the way for easy drug screening against PD.

71 hPSCs) offer many potential applications for drug screening and 'disease in a dish' assay capabilitie

72 sculogenic cell types for basic research and drug screening and can contribute to angiogenic regenera

73 on of "humanized" models for high throughput drug screening and candidate gene validation with except

74 ill accelerate clinical applications such as drug screening and cell therapy as well as shedding ligh

75 promise in disease modelling, pharmaceutical drug screening and cell therapy for Huntington's disease

76 tial cell source for heart disease modeling, drug screening and cell-based therapeutic applications.

77 Cs) are used as platforms for disease study, drug screening and cell-based therapy.

78 h could aid the growing use of C. elegans in drug screening and chemical genomics.

79 ing an increasingly useful in vitro tool for drug screening and delivery to pathological tissues and

80 classifying cells based on their viability, drug screening and detecting populations of malignant ce

81 toward various forms of xenograft models for drug screening and development.

82 chanisms, and metabolic pathways, through to drug screening and discovery as well as medical imaging.

83 ticipate the widespread adoption of MPSs for drug screening and disease modeling.

84 used for various applications such as early drug screening and disease modeling.

85 onic stem cells (hESCs) for therapeutic use, drug screening and disease modelling will require cell l

86 PSCs) are essential to personalized in vitro drug screening and disease study.

87 s for focal use and human cell test beds for drug screening and drug discovery, are emerging.

88 ial cardiomyopathies as well as for in-vitro drug screening and drug discovery.

89 form will greatly facilitate high-throughput drug screening and electrophysiological characterization

90 without the use of solvents, can accelerate drug screening and enable continuous manufacturing, whil

91 LTP in AD, thus opening up a new avenue for drug screening and evaluation of strategies for alleviat

92 this powerful new set of tools for improved drug screening and for investigating early mechanisms dr

93 ngineered environments open new -avenues for drug screening and fundamental studies of wound healing,

94 igh-throughput, single-molecule detection in drug screening and genomic analysis are discussed.

95 ation of high-quality chemical libraries for drug screening and in applications such as drug repositi

96 Future applications such as drug screening and in point of care applications are the

97 in vivo models of C. difficile infection for drug screening and lead optimization.

98 of the technology has limited its impact on drug screening and lead optimization.

99 y diverse human sensory neurons suitable for drug screening and mechanistic studies.

100 gs validate a unique BCSC culture system for drug screening and offer preclinical proof of concept fo

101 aterial for therapeutic intervention such as drug screening and potentially also for cell-based thera

102 ul platform in cases such as high-throughput drug screening and prolonged drug release.

103 nerative medicine, modeling of lung disease, drug screening and studies of human lung development.

104 nerative medicine, modeling of lung disease, drug screening and studies of human lung development.

105 iological models of human cancers for use in drug screening and studying cancer biology.

106 ial for investigating PPIs in the context of drug screening and target validation applications.

107 ranslational pain research, and enable rapid drug screening and testing of newly engineered opsins.

108 form, to provide a powerful tool amenable to drug screening and the design of therapeutics to treat a

109 The results have implications for drug screening and the determination of heat capacity ch

110 hat are applicable to regenerative medicine, drug screening and the establishment of disease models.

111 ion kinetics for many applications including drug screening and the investigation of the mechanisms o

112 ially be used for the treatment of diabetes, drug screening and the study of beta-cell biology.

113 tential applications, including personalized drug screening and therapeutic strategies for liver fail

114 cal environment for MSC in disease modeling, drug screening and tissue engineering.

115 genetic backgrounds would be beneficial for drug screening and to provide a source of cells to be us

116 cs screening-e.g., for clinical phenotyping, drug screening and toxicity testing.

117 ernatives to animal and clinical studies for drug screening and toxicology applications.

118 y emerging as a promising model organism for drug screening and translational neuroscience research.

119 as a tool for medium-throughput antimalarial drug screening and vaccine development.

120 We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlo

121 t, therefore, be amenable to industrial (eg, drug screening) and clinical (eg, cardiac repair) applic

122 nderstanding of cancer pathology, anticancer drug screening, and cancer treatment development.

123 otency, and allow in-vitro disease modeling, drug screening, and cell replacement therapy.

124 tial cell source for heart disease modeling, drug screening, and cell-based therapeutic applications.

125 ker discovery, molecular interaction assays, drug screening, and clinical diagnostics.

126 f applications such as inflammation studies, drug screening, and coculture interactions.

127 use as an efficient model for candidate NPC1 drug screening, and demonstrated similarities in hepatic

128 valuable resource for regenerative medicine, drug screening, and developmental studies.

129 Tissue engineering, gene therapy, drug screening, and emerging regenerative medicine thera

130 llenge for applications in disease modeling, drug screening, and heart repair.

131 (iPSC) technology for the cellular therapy, drug screening, and in-vitro modeling of neurodegenerati

132 mplications in functional molecular studies, drug screening, and iPS cell-based platforms for disease

133 ould have broad utility in disease modeling, drug screening, and regenerative medicine.

134 using iPSC technology for disease modeling, drug screening, and the development of stem cell therape

135 such as cancer detection, probe development, drug screening, and therapy monitoring.

136 re unlikely to be found through conventional drug screening, and they include kinase inhibitors and d

137 parasites suitable for in vitro and in vivo drug screening, and we evaluated the basis of drug susce

138 fmol, which would be a useful attribute for drug screening applications or testing of small quantiti

139 yte detection and is particularly suited for drug screening applications.

140 nsplantation, human antibody generation, and drug screening applications.

141 underscoring the potential of the system for drug screening applications.

142 ng to make the system a more viable tool for drug screening applications.

143 s very attractive for tissue engineering and drug screening applications.

144 We used a phenotypic drug screening approach to identify ethoxyquin as a pote

145 des a powerful tool for disease modeling and drug screening approaches.

146 The basis of the next generation of drug-screening approaches is set to be in silico risk pr

147 d by topoisomerase inhibitors in an oncology drug screening array and altered variant composition of

148 ystem as an alpha-synuclein anti-aggregating drug screening assay a panel of 10 drugs was tested.

149 cal proteomics and an organotypic cell-based drug screening assay, we determine the functional role o

150 nal multi-assay algorithm and antiretroviral drug screening assay.

151 limit of 10 pg/ml, as well as demonstrated a drug screening assay.

152 atform provided a rapid ( approximately 1 h) drug screening assay.

153 Using a cell-based drug-screening assay, we identified Acriflavine (ACF), a

154 Fluorescent drug screening assays are essential for tyrosine kinase

155 New reliable and cost-effective antimalarial drug screening assays are urgently needed to identify dr

156 Drug screening assays identified a compound targeting th

157 es a potential natural substrate peptide for drug screening assays, and also reveals a potential func

158 enerative diseases and in proof-of-principle drug-screening assays.

159 l microarray imaging approach for anticancer drug screening at specific cancer protein-protein interf

160 lytes, immunoassays, gene expression assays, drug screening, bioimaging of live organisms, cancer stu

161 Using in silico drug screening by Connectivity Map followed by empirical

162 low exchange that are not easily amenable to drug screening by traditional NMR methods.

163 ection is of great demand in gene profiling, drug screening, clinical diagnostics and environmental a

164 sing a panel of AMD biomarkers and candidate drug screening, combined with transcriptome analysis, we

165 However, drug screening contains a number of key constraints that

166 es used by the National Cancer Institute for drug screening correlated significantly with tumor resis

167 Next generation drug screening could benefit greatly from in vivo studie

168 n addition, the use of pluripotent cells for drug screening could enable routine toxicity testing and

169 an algorithm that integrates high-throughput drug screening data, comprehensive kinase inhibition dat

170 blicly available, high-quality DNA, RNA, and drug screening data.

171 for summarizing high-throughput, image-based drug screening data.

172 on data linked to high-quality DNA, RNA, and drug-screening data have not been available across a lar

173 cally available genomic, transcriptomic, and drug-screening data.

174 of organ-on-a-chip systems, high-throughput drug screening devices, and in regenerative medicine.

175 ogy for development of robust biosensors and drug screening devices.

176 and represents a promising cellular tool for drug screening, diagnosis and personalized treatment.

177 potential for future applications including drug screening, diagnostic applications and functional a

178 here has been limited progress in iPSC-based drug screening/discovery for liver diseases, and the low

179 ssues offer enormous potential as models for drug screening, disease modeling, and regenerative medic

180 recapitulate human responses are needed for drug screening, disease modeling, and, ultimately, kidne

181 During a high-content drug screening effort, we identified AS601245 as a poten

182 t of the National Cancer Institute's (NCI's) drug screening effort.

183 Drug screening efforts and subsequent structural and mec

184 ro studies of degenerative mechanisms or for drug screening efforts.

185 ience and neuroendocrine research as well as drug screening efforts.

186 re also likely applicable to high-throughput drug screening, evident from the fact that TC is an anti

187 Through a blind large-scale drug screening, five clinical drugs were identified to r

188 many potential applications in modeling and drug screening for airway diseases.

189 Drug screening for antimalarials uses heme biocrystalliz

190 We describe a new approach to proteome-wide drug screening for detection of on- and off-target bindi

191 nd heterodimer BRET assays are applicable to drug screening for dimer-selective selective ER modulato

192 tool for basic discovery and high-throughput drug screening for G-protein-coupled receptors and ion c

193 d to be useful for regenerative medicine and drug screening for liver diseases.

194 en developed and validated in the context of drug screening for schistosomiasis, one of the most impo

195 sing cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental disorders.

196 in vivo tool for high-throughput therapeutic drug screening for the improvement of muscle phenotypes

197 To facilitate drug screening for this anaerobic protozoan, we develope

198 enes which can be used for disease modeling, drug screening, gene correction and future in vivo appli

199 hnologies are urgently required for reliable drug screening given a worldwide epidemic of prescriptio

200 d using these small, inexpensive embryos for drug screening has become de rigueur.

201 of this biosensor in future high throughput drug screening has the important potential to help ident

202 seful for monitoring therapy response or for drug screening; however, the reproducibility of serial s

203 ffective alternative to conventional labeled drug screening immunoassays with potential for translati

204 ate this microfluidic device will facilitate drug screening in a relevant microenvironment thanks to

205 tform for genotype-phenotype correlation and drug screening in any human myelin disorder.

206 pigenetic biomarkers through high-throughput drug screening in approximately 1,000 molecularly annota

207 Our work lays the groundwork for label-free drug screening in pharmaceutical science and industry.

208 trast could be a potentially useful tool for drug screening in preclinical models.

209 to antihypertensive treatment at 6 months by drug screening in urine/plasma samples from 85 patients.

210 disease such as cancer, for high throughput drug screening in vitro.

211 Cell-based drug screenings indicate that tumors displaying c-MET ge

212 omimetic assays for interaction analysis and drug screening involving membrane components.

213 The applicability for drug screening is demonstrated by studying the effects o

214 Drug screening is facilitated by the incorporation of a

215 opment of a biomimetic 3D culture system for drug screening is necessary to fully understand the in v

216 need for a liver-on-a-chip tissue model for drug screening is particularly important in tissue engin

217 by a complete cell-based assay for efficient drug screening is performed showing a clear correlation

218 Conventional anticancer drug screening is typically performed in the absence of

219 s to use differentiated cells for therapy or drug screening, it may not matter whether these stem cel

220 such as photodynamic therapy for accelerated drug screening, magnetically guided controlled drug deli

221 This convenient method for drug screening may facilitate the development of antivir

222 ons, we developed an efficient combinatorial drug screening method called the Feedback System Control

223 A single-cell drug screening method is described that produces rich si

224 The development of this single-cell drug screening method is presented, and fluorescent and

225 ues were analyzed initially by an anticancer drug-screening method based on a sulforhodamine B assay.

226 d high-throughput and reliable point-of-care drug screening methodologies.

227 Here, by using in silico drug-screening methods, we discovered that Celastrol, a

228 inatorial printing, high-throughput parallel drug screening, modular disposable cartridge, and biocom

229 es used by the National Cancer Institute for drug screening (NCI-60).

230 ghlight the PM as a high-fidelity target for drug screening of Kv channels.

231 However, high-throughput drug screening of P450s is limited by poor protein stabi

232 onstrate the applicability of our method for drug screening on dried blood spots showing excellent li

233 s and should be valuable for high-throughput drug screening or biointeraction studies.

234 em cells are a potential source of cells for drug screening or cell-based treatments for neurodegener

235 for relevant biosensing applications such as drug screening or cellular chips.

236 nique in scientific research, pharmaceutical drug screening or toxicity testing.

237 croRNAs (miRNAs) in the 60 cell lines of the drug screening panel maintained by the Nation Cancer Ins

238 nes from the National Cancer Institute (NCI) drug-screening panel (NCI-60 panel).

239 f the National Cancer Institute's anticancer drug-screening panel for apoptosis sensitivity to S2 and

240 , as a result, lead to new clinical care and drug screening paradigms, are discussed.

241 s demonstrate the efficacy of our model as a drug screening platform and a promising tool to investig

242 We validate our model as a drug-screening platform by identifying several compounds

243 omatography- mass spectrometry (LC-MS) based drug-screening platform we show that Metformin, a widely

244 HIV-1 diagnosis, as well as high-throughput drug screening platforms.

245 f human intestinal disease and in developing drug-screening platforms that more accurately represent

246 Proof of principle that the gene panel shows drug screening potential was obtained using a well-estab

247 l generic analytical applications, including drug screening, prion strain discrimination, biohazard s

248 as a rapid and reliable in vitro method for drug screening prior to in vivo testing.

249 A simple and cost-effective two-tier drug screening procedure comprises a 'dedicated' NIR spe

250 itro systems have significantly advanced the drug screening process as 3D tissue models can closely m

251 ghput fashion could dramatically improve the drug screening process.

252 h can have a myriad array of applications in drug screening, programmable tissue engineering, drug de

253 stic studies of homologous recombination and drug screening programs.

254 ifferentiation into lineages for large-scale drug-screening programs and clinical use.

255 udy, we established a robust high-throughput drug screening protocol by using a recombinant RSV repor

256 based studies, including structure-function, drug screening, proton exchange, pH, and other titration

257 bility of cells cultured in microsystems for drug screening purposes is usually tested with a variety

258 SM or CSPalpha aggregation as biomarkers for drug screening purposes.

259 inal cells for regenerative medicine and for drug-screening purposes, as well as an in vitro model of

260 mation from the descriptions of over 100,000 drug screening-related assays in rats and mice.

261 lular plasticity, possibly in the context of drug screening research and of future cell-replacement t

262 High-throughput drug screening revealed that bromodomain and extra-termi

263 y engraft in recipient mice, and preliminary drug screening reveals mutation-specific vulnerabilities

264 Targeted drug screening reveals that SCLC with high MYC expressio

265 have the potential to be used for automated drug screening routines.

266 nt in vitro models of muscle dystrophies and drug screening strategies, as well as providing a source

267 Using this model, we designed a drug screening strategy based on the pupal lethality phe

268 ts establish the feasibility of a cell-based drug screening strategy targeting the p53 transcription

269 uired make zebrafish the model of choice for drug screening studies, when a valid disease model is av

270 potential in other clinical applications and drug-screening studies.

271 In the future, iMPCCs could prove useful for drug screening, studying molecular mechanisms underlying

272 biomolecules can yield useful platforms for drug screening, synthetic biology applications, diagnost

273 ough high-throughput genomics and innovative drug-screening systems.

274 d on MOCOS expression, and paves the way for drug screening targeting MOCOS and/or the purine metabol

275 ology as an inexpensive, rapid, and reliable drug screening technology.

276 re amenable for biomarker identification and drug-screening testing and led to the identification of

277 Applied to promyelination drug screening, the method uniquely enabled the identifi

278 ity of this organism for large-scale in vivo drug screening, thus providing unprecedented opportuniti

279 s rapid disease modeling and high-throughput drug screening to alleviate astrocyte-derived toxicity.

280 cations ranging from medical diagnostics and drug screening to chemical and biological warfare detect

281 -germline neurofibroma model for preclinical drug screening to identify effective therapies.

282 , and develop platforms for, high-throughput drug screening to identify novel compounds to prevent an

283 N transcription, thus making it an efficient drug screening tool that can be used for therapeutic int

284 seful for mechanical injury studies and as a drug screening tool, and it could serve as a foundation

285 ential of constitutively active receptors as drug screening tools and the interdependence of ligand s

286 models of eye disease as useful preclinical drug screening tools in studies to identify molecular me

287 otent cells applicable to disease modelling, drug screening, toxicology tests and, ultimately, autolo

288 llmarks of tissue-based bioassays, including drug screening, tumor dissemination, cell co-culture, an

289 ted the feasibility of effective large-scale drug screening using an iPSC-based disease model and hig

290 Through a proof-of-principle drug screening using BICA, we found that danusertib, an

291 of lead compounds to patients, we conducted drug screening utilizing our established library of clin

292 his system's biotechnological application in drug screening was successfully demonstrated by the N-ox

293 Using in vitro drug screening, we identified 211 amino-acid substitutio

294 Using drug screening, we identified tumor necrosis factor-alph

295 Through a series of data analysis and drug screening, we identified two compounds (i.e., NSC-3

296 al ligand-binding approach for antipsychotic drug screening where competitive binding of a novel APD

297 ve the efficacy and accuracy of OCT in vitro drug screening will greatly contribute to the field of c

298 eatures of less than 100 nm, high-throughput drug screening will require facile methods to incorporat

299 opens a new avenue to early diagnostics and drug screening with high sensitivity.

300 device and cell-free protein expression for drug screening, with advantages in less reagent consumpt